Novartis Japan Launches Four New Products
This article was originally published in PharmAsia News
Executive Summary
Swiss drug maker Novartis' Japanese subsidiary, Novartis Pharma K.K. launched four products in the Japanese market March 13. The new drugs are Xolair, Co-Dio, Tasigna and Lucentis. The first asthma antibody drug approved in Japan, Xolair (omalizumab), is used to treat severe asthma that can not be controlled by other drugs and is administrated every other week or every four weeks. Co-Dio is a hypertension combo drug of valsartan and hydrochlorothiazide. Tasigna (nilotinib) is indicated for adult chronic myelogenous leukemia patients resistant or intolerant to prior therapy. Antibody drug Lucentis (ranibizumab) treats age-related macular degeneration. The four products were approved in Japan in January. (Click here for more - Japanese language
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.